Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on July 25, 2021, covering events occurring on July 25 and July 27, 2021. The Company operates in the healthcare sector and is focused on expanding its product portfolio through strategic licensing agreements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The primary financial disclosure relates to a new contractual obligation:
- Total Potential Milestone Payments: Up to $18,000,000 payable to Sintetica S.A.
- Immediate Obligation: $5,000,000 due within 30 days of signing the agreement.
- Remaining Milestones: $13,000,000 contingent upon achieving specific regulatory and commercial milestones.
- Ongoing Costs: Per unit transfer price for supply and per unit royalty on units sold.
Material Changes
The material change reported is the entry into a definitive License and Supply Agreement with Sintetica S.A. on July 25, 2021. This agreement grants Harrow Health exclusive license and marketing rights to the patented ophthalmic drug candidate AMP-100 in the United States and Canada. Sintetica retains responsibility for regulatory filings for AMP-100 in the U.S.
Outlook, Risks, and Unusual Items
Agreement Terms: The agreement has an initial term of ten years, with an option for a ten-year extension subject to meeting certain sales thresholds.
Management Commentary: The Company issued a press release on July 27, 2021, announcing the exclusive North American licensing arrangement.
Risks and Contingencies: Future payments are contingent on regulatory approvals and commercial sales performance. The filing notes that the summary is qualified by the full text of the agreement, which was expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the exact terms of the $18 million milestone payment schedule and the specific regulatory/commercial triggers.
- Confirm the per unit transfer price and royalty rates for AMP-100.
- Review the full License and Supply Agreement filed as an exhibit to the Q2 2021 Form 10-Q.
- Assess the impact of the $5 million immediate payment on the Company's current cash position and liquidity.
- Monitor Sintetica's progress on U.S. regulatory filings for AMP-100.